Article Text

Download PDFPDF
Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease
  1. H Watanabea,
  2. T Iedaa,
  3. T Katayamab,
  4. A Takedaa,
  5. I Aibab,
  6. M Doyua,
  7. M Hirayamaa,
  8. G Sobuea
  1. aDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya 466–8550, Japan, bDepartment of Neurology, Higashi Nagoya National Hospital, Japan
  1. Dr G Sobuesobueg{at}


Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake was measured in 11 patients with dementia with Lewy bodies (DLB), 10 patients with Alzheimer's disease (AD), and 10 age matched control subjects. The severity of cognitive impairment and duration of symptoms in patients with DLB matched that in the patients with AD. The heart/mediastinum (H/M) ratio of MIBG uptake in the patients with AD was indistinguishable from that in the control subjects. However, the H/M ratio in all patients with DLB was significantly lower than that in the patients with AD and control subjects (p<0.001). These findings indicate that local myocardial sympathetic nerves are affected in DLB and that cardiac 123I-MIBG scintigraphy may provide a means of differentiating DLB from AD.

  • meta-iodobenzylguanidine
  • dementia with Lewy bodies
  • Alzheimer's disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.